No images? Click here
NEWS
EPFL offers new Masters including Neuro-X and Quantum Science
"EPFL constantly adapts its education offer to the new developments in science and engineering, as well as to the evolution of our society, the emerging needs of its economy as well as its numerous challenges."
Prof. Pierre Dillenbourg, Associate Vice-President for Education
Objects can now be 3D-printed in opaque resin
A team of EPFL engineers has developed a 3D-printing method that uses light to make objects out of opaque resin in a matter of seconds. Their breakthrough could have promising applications in the biomedical industry, such as to make artificial arteries.
Exoskeleton device helps stroke victims regain hand function
Working closely with users and therapists, EPFL spin-off Emovo Care has developed a light and easy-to-attach hand exoskeleton for people unable to grasp objects following a stroke or accident. The device has been successfully tested in several hospitals and rehabilitation centers.
Teaming up to solve water-related problems in Ghana Two EPFL students, Nour Ghalia Abassi and Mohamed Ali Dhraief, spent ten days in Ghana working on water-related projects.
NeuroMechFly: a digital twin of Drosophila EPFL scientists have developed a digital model of the fruit fly, Drosophila melanogaster, which realistically simulates the movements of the animal. The twin is a big step towards reverse engineering the neuromechanical control of animal behavior, and developing bioinspired robots.
EPFL Racing Team bets on Artemis to bring home the wins The team unveiled its latest car yesterday evening at EPFL’s new makerspace. Their speedster will compete in four Formula Student Electric races throughout Europe this summer.
Turning drug discovery into speed dating EPFL spin-off ArcoScreen has developed a platform that turns the discovery of new drugs for Alzheimer’s and Parkinson’s disease, diabetes and cancer from a marathon into a sprint. The firm’s microfluidic readout system assesses the response of G-protein-coupled receptors (GPCRs) to new substances, delivering significant time and financial gains for pharmaceutical companies.
|
EVENTS 5-9.06.2022 |
